Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 12 Show results per page	View Search Criteria \| Help With Results

Last Modified: 12/20/2006 First Published: 2/21/2003


1.		Phase III Randomized Study of Neoadjuvant Releasing Factor Agonist Therapy and Antiandrogen Therapy With or Without Docetaxel And Estramustine in Patients With Locally Advanced Prostate Cancer or With A High Risk of Relapse

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Under 80				Other				FRE-FNCLCC-GETUG-12/0203 EU-20238, NCT00055731

Last Modified: 5/14/2008 First Published: 2/18/2005


2.		Phase III Randomized Study of Neoadjuvant Androgen Blockade Therapy Comprising Triptorelin and Flutamide Followed by Conformal External Beam Radiotherapy and Continued Androgen Blockade Therapy Versus Conformal External Beam Radiotherapy Alone in Patients With Stage II or III Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Under 75				Other				FRE-FNCLCC-GETUG-14/0207 EU-20503, NCT00104741

Last Modified: 1/13/2009 First Published: 1/25/2006


3.		Phase III Randomized Study of Androgen Suppression (AS) and Radiotherapy (RT) Versus AS and RT Followed by Docetaxel and Prednisone in Patients With Localized, High-Risk Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				RTOG-0521 NCT00288080


4.		External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Not specified				Other				2003-0819 NCT00388804

Last Modified: 1/11/2009 First Published: 12/3/2007


5.		Phase III Randomized Study of Prostate Bed Radiotherapy (PBRT) Alone Versus Short Term Androgen Deprivation Comprising Antiandrogen and Luteinizing Hormone-Releasing Hormone Agonist Therapy and Pelvic Lymph Node Radiotherapy With Versus Without PBRT in Patients With a Rising Prostate-Specific Antigen After Radical Prostatectomy for Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				RTOG-0534 RTOG 0534, NCT00567580

Last Modified: 1/6/2009 First Published: 3/31/2008


6.		Phase III Randomized Study of Androgen Suppression Therapy and Radiotherapy With Versus Without Docetaxel in Patients With High-Risk Localized Adenocarcinoma of the Prostate

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Not specified				NCI				CAN-NCIC-PR12 PR12, NCT00651326

Last Modified: 12/8/2008 First Published: 1/24/2005


7.		Phase II Study of Bortezomib With or Without Combined Androgen Blockade Therapy in Patients With Early Relapsed Adenocarcinoma of the Prostate

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				Over 18				Other				MUSC-031218 100822, MUSC-HR-11357, NCT00103376


8.		Study of OGX-011 Given Prior to Radical Prostatectomy in Patients With Localized Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				R04-0092 NCT00138918


9.		Intermittent Hormone Therapy in Men With Localized Prostate Cancer After Radiation Therapy or Radical Prostatectomy.

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				over 21				Other				06-2040-A-02 L-8863, NCT00223665

Last Modified: 8/29/2008 First Published: 3/16/2007


10.		Phase II Randomized Pilot Study of Flutamide With Versus Without Vaccine Therapy Comprising Recombinant Vaccinia Prostate-Specific Antigen Vaccine and Recombinant Fowlpox Prostate-Specific Antigen Vaccine in Patients With Androgen-Insensitive, Nonmetastatic Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				NCI-07-C-0107 07-C-0107, 7354, NCT00450463

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute